Patent ID: 6117898
Filing Date: 2000-09-12
Classification: A61P,C07D

Abstract:
A method of treatment or prophylaxis of diseases or conditions in which preferential inhibition of the neuronal isoform of NOS is beneficial which comprises administering to a person in need thereof a therapeutically effective amount of a compound of formula (I) ##STR17## wherein D represents a five membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, N or S, optionally substituted at a carbon atom by halogen, trifluoromethyl, alkyl C1 to 6, nitro, cyano, and which is connected to the remainder of the compound of formula I through a carbon atom;A represents N(X) or CH(--(CH.sub.2).sub.m --NXY);U represents NH, O or CH.sub.2 ;V represents (CH.sub.2).sub.a ;W represents (CH.sub.2).sub.b ;a and b independently represent an integer 0 to 3, provided that a+b is in the range 1 to 3;X and Y independently represents hydrogen, alkyl C1 to 6, or the group --(CH.sub.2).sub.n Q or --NXY represents piperidinyl, pyrrolidinyl, morpholinyl or tetrahydroisoquinolinyl;Q represents biphenyl or phenyl optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6, perfluoroalkyl C1 to 6, halogen, nitro or cyano;m represents an integer 0 to 5;n represents an integer 0 to 6;or the chain U--V--A--W is as defined above save that it may be unsaturated,or the chain U--V--A--W may represent --NH--CH.sub.2 --CH.sub.2 --O-- substituted at a carbon atom by the group --(CH.sub.2).sub.m --NXY, wherein m, X and Y are as defined above, or a pharmaceutically acceptable salt thereof.